News

In the delivery of scalable cell therapies, there is a fundamental need to derive viable cells in vitro. In addition to developing cell cultures that mimic in vivo conditions for the maintenance of target cell types, cells need to acquire and develop specific therapeutic characteristics.

Join our speakers, Dr. Zoe Hewitt (UK Regenerative Medicine Platform), Dr. Owen Rackham (Duke-NUS Medical School) and Dr. Rodrigo Santos (Mogrify) to discuss how epigenetics can be implemented to drive cell identity and support the development of scalable cell therapies under GMP compliance.